Analytic Investors’s Corcept Therapeutics CORT Stock Holding History

Analytic Investors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.06M	Buy	163,426 +64,697	+66%	+$376K	0.01%	359
2016 Q2	$539K	Buy	98,729 +19,148	+24%	+$99.6K	0.01%	466
2016 Q1	$372K	Hold	79,581	–	–	﹤0.01%	513
2015 Q4	$396K	Buy	79,581 +65,136	+451%	+$294K	0.01%	525
2015 Q3	$54K	Buy	+14,445	New	+$73.3K	﹤0.01%	542

Other funds holding CORT

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Analytic Investors's CORT Position: Q3 2016 in Review

Analytic Investors increased its Corcept Therapeutics (CORT) stake by 66% in Q3 2016, buying an estimated $376K and bringing the position to 163,426 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #359.

Analytic Investors first reported a position in CORT in Q3 2015 and has held it in 5 quarters since. 110 funds tracked by Wall St. Rank hold CORT as of Q3 2016.

Analytic Investors held 163,426 shares of Corcept Therapeutics worth $1.06M as of Q3 2016.
Analytic Investors bought 64,697 Corcept Therapeutics shares in Q3 2016, an estimated $376K.
Corcept Therapeutics made up 0.01% of Analytic Investors's portfolio in Q3 2016, its #359 holding.
Analytic Investors first reported a position in Corcept Therapeutics in Q3 2015 and has held it in 5 quarters since.
110 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.